Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponesimod in Moderately to Severely Active Ulcerative Colitis
NCT07686081Phase 3Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Ponesimod (VSP-128) with Placebo (2 arms). Primary endpoint: Clinical Remission at 16 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ponesimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07686081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686081.